

INVESTOR

PRESENTATION

NASDAQ: SYRA

December 8, 2023

FORWARD-LOOKING STATEMENTS

Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute 'forward-looking statements.' The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Investors should read the risk factors set forth in our Form 10-Q for the quarter ended September 30, 2023, and in our registration statement on Form S-1 and other periodic reports filed with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the uncertainties related to market conditions. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Syra Health specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SYRA HEALTH

Syra Health provides innovative services and technology solutions to address some of healthcare's biggest challenges.

Syra Health specializes in high-margin revenue areas such as

behavioral and mental health, digital health, and population health while maintaining consistent revenues within the well-established healthcare workforce market.

Syra Health's solutions are centered on prevention, improved access, and affordable care.







OUR BUSINESS UNITS

- Behavioral and Mental Health
- Digital Health
- Population Health Management
- Mealthcare Workforce
- Mealth Education



Academic Institutions

BEHAVIORAL & MENTAL HEALTH

Syrenity is focused on the prevention of mental and behavioral health concerns

With its evidence-based approach,

Syrenity includes an AI-backed diary

When needed, Syrenity provides 24/7

access to licensed therapists via telehealth.



MARKET POTENTIAL

U.S. Behavioral health market:

\$132.4 billion

by 2027.

According to the National Alliance on Mental Illness or NAMI, 1 in 5 adults living in the U.S. experiences mental illness annually.

PRODUCTS AVERAGE PROJECT SIZE

- Per member \$10 per month
- Telehealth based on therapist range is \$60 to \$250 per session

SERVICES AVERAGE PROJECT SIZE

• \$6000 per psychological evaluation

DIGITAL HEALTH



SyraBot is a conversational, AI-backed chatbot solution that offers real-time customer support any time. SyraBot is available in up to 200 languages and at a fifth-grade reading level, making it fully accessible.

CarePlus

CarePlus is an innovative and affordable electronic medical record (EMR) solution developed by Syra Health to cater to the unique needs of small to mid-sized healthcare organizations. CarePlus streamlines clinical workflows, reduces errors, and seamlessly integrates with labs, radiology and other EMRs.

Cybersecurity

We host our cloud-based solutions on secure and compliant cloud platforms, with stringent security measures and regular security audits.

Modernization

We help organizations update and improve their legacy healthcare applications and systems to enhance their functionality, performance, and security. Nasdaq: SYRA

MARKET POTENTIAL

U.S. Digital Health Market size of

\$211B

expected to grow at CAGR of

18.6%

PRODUCTS

AVERAGE PROJECT SIZE

- Chatbot \$350K/yr
- EMR \$350K/yr

SERVICES

AVERAGE PROJECT SIZE

- Cybersecurity \$600K per project
- Modernization \$1M/yr

POPULATION HEALTH



EPIDEMIOLOGY

Our experienced team offers epidemiological services to state and local agencies to improve public health. We analyze emerging trends and patterns in health using data-driven methods, providing a deeper understanding of public health to support organizations in shaping evidence-based policies and practices.



DATA HUB AND SERVICES

Our Syra Health data hub is a sophisticated solution for mining relevant public health data with the ability for partners to add custom data to the mix. Our services include a vulnerability index and disease-centric analysis. We also incorporate predictive models for insights and risk prediction.

MARKET POTENTIAL

U.S. Population health management Market size of

\$20.6B

expected to grow at CAGR of

19.5%

SERVICES

AVERAGE PROJECT SIZE

- Data Hub \$600K per project
- Epidemiology \$300k per project

MARKET POTENTIAL

Market Size of

\$83B

expected to grow at a CAGR of 10%



HEALTHCARE TRAINING

To decrease health disparities and improve patient outcomes and satisfaction, we have a team of subject matter experts that create training for employees and staff of health organizations, pharmaceutical companies, payers, and large healthcare employers.



PATIENT EDUCATION

We offer comprehensive patient education solutions and services to patients, provider groups, payers, health care institutions, and government health agencies to improve intrinsic health education which we believe will lead to increased patient satisfaction, positive experiences and better health outcomes.

SERVICES

AVERAGE PROJECT SIZE

• \$600K/Yr

HEALTHCARE WORKFORCE



We evaluate the workforce needs of our partner organizations and use agile implementation staffing methodologies to make it as seamless and cost-efficient as possible to expand our partner's clinical personnel.



WORKFORCE OPTIMIZATION STRATEGIES

Syra Health offers workforce optimization strategies that help healthcare organizations optimize staffing levels, improve productivity, and reduce costs. By leveraging data-driven insights and predictive analytics, Syra Health identifies staffing gaps, streamlines workflows.



COMPREHENSIVE SUPPORT SERVICES

Syra Health provides the necessary training and educational services to ensure quality clinical personnel. Syra Health also offers social support, mental and behavioral solutions, and digital support solutions customized to the individual partner needs.

MARKET POTENTIAL

The U.S. healthcare workforce

Market Size of \$24.1B

expected to grow at CAGR of

5.6%

SERVICES

AVERAGE PROJECT SIZE

Staffing - \$300K per account

BEHAVIORAL & MENTAL HEALTH

CONTRACTS

NAME	STATE	CONTRACT PERIOD	VALUE
E & I Cooperation Syrenity	All US	2023 - 2028	
Dept. of Child Services (DCS)/Competency Attainment Services	IN	2022-2024 (+ 2 years extension possible)	~\$100K per year
Camden County Health Department/ Psychological Evaluations	NJ	2023 - 2025	~50K per year

DIGITAL HEALTH

CONTRACTS

CONTRACT	STATE	CONTRACT PERIOD	VALUE
Centene/ MHS - Chatbot	IN	2022 – 2026 (+2 years extension)	\$2.2 M

POPULATION HEALTH


CONTRACTS


NAME	STATE	CONTRACT PERIOD	VALUE
Department of Behavioral Health/Epidemiological Studies	DC	2023 (1 year)	\$250K one time
Dept of Health/BRFSS	IN	2023 -2027	~350K annual
State of Texas /City of San Antonio - Racial and Ethnic Approaches to Community Health (REACH) program evaluation	тх	2023 - 2028	\$275K
Dept of Human Services/ CLAS services	MN	2023-2025	\$212K
City of Boston/ Boston Public Health Commission	МА	2023	
Dept of Mental Health/State Epidemiological Outcomes Workgroup	IN	2021- 2026	\$1.246M

CONTRACTS	STATE	CONTRACT PERIOD	VALUE
Department of Behavioral Health/BHA/CPEP and SEH	DC	2023 (+ 5 years extension)	Up to\$4.75M
Department of Behavioral Health/BHA/SEH	DC	2023 (+ 5 years extension)	Up to \$8.90M
Commissioner of Human Services	MN	2023-2028	
Dept. of General Services/ Statewide contract	VA	2023-2024 (+ 2 years extension)	
Dept. of Corrections	ОК	2023 (+3 years extension)	
YesCare/Dept. of Corrections	AL	2023 (+ 2 years extension)	
Indiana Veterans Home	IN	2023 (annual extension)	
Ohio Veterans Home	ОН	2023 (+3 years extension)	
Dept of Administration - Statewide	KS	2023-2028 (+6 years extension)	
Osawatomie State Hospital	KS	2023-2028	
Dept of Corrections	VA	2023-2025	
State of West Virginia – Statewide	WV	2023-2024	
Dept. of Mental Health & Addiction (DMHA) /Neuro Diagnostic Institute	IN	2021-2025 (+2 years extension)	Up to \$17.5M

REVENUE DISTRIBUTION & MARGIN INCREASE

Nasdaq: SYRA





REVENUE



Pro Forma Pos	Pro Forma Post IPO Capitalization Table		IPO	
Class A common stock	5,588,298 Shares		Offering Size	1,615,000 Units ⁽²⁾
Class B Common Stock	833,334 ⁽¹⁾ Shares		Price	\$4.125 per Unit
Options	To purchase 326,435 shares of Class A common stock		IPO Net Proceeds	\$4.7 M
Warrants	To purchase 1,857,250 shares of Class A common stock		Management Ownership After IPO	47%
Total Outstanding Shares (fully diluted)	13,921,642 Shares		Management Voting Rights After IPO	56.2%

⁽¹⁾ Each outstanding share of Class B common stock is convertible into 10 shares of Class A common stock and are entitled to 16.5 shares per vote.

⁽²⁾ Each Unit consists of one share of Class A common stock and one warrant to purchase one share of Class A common stock at an exercise price of \$6.50 per share, exercisable until the fifth anniversary of the issuance date.

INVESTMENT SUMMARY



Secured a five-year \$4.75 million contract with the District of Columbia's Department of Behavioral Health (DBH), to support DBH's mental health initiatives



Announced a strategic agreement with E&I Cooperative Services to market Syrenity to E&I's 6,000 plus college and university members nationwide



Received a two-year contract extension, with a total contract amount worth \$1.2M, with the Indiana Division of Mental Health and Addiction and FSSA to chair and manage the State of Indiana's Epidemiological Outcomes Workgroup



Launched CarePlus, an electronic medical record (EMR) system designed specifically for small to mid-sized healthcare organizations. CarePlus is an easy-to-use, secure, and scalable platform that allows for streamlining clinical workflows and integrating labs, radiology, and telehealth



Launched Syrenity, a mental health product that proactively identifies the negative factors impacting mental health and integrates telehealth for mental health prevention and treatment



In October 2023, closed on \$6.7 million IPO financing and began trading on the NASDAQ

SYRA HEALTH EXECUTIVE LEADERSHIP



Deepika Vuppalanchi, PhD
Chief Executive Officer,
Board Director

Deepika Vuppalanchi is the CEO, Director of the Company, and Co-founder of Syra Health. She has 10+ years of experience in healthcare and medical research. She was a senior medical director at Precision For Value, a medical education director at Symbiotix and DWA Healthcare Communications. She holds a PhD and Master's degree in Molecular Biology and Genetics from the University of Delaware and a Bachelor's in Microbiology from Osmania University. Her experience working with stakeholders in academia, pharmaceutical, and biotechnology companies makes her a valuable member of Syra Health's Board of Directors.



Sandeep Allam, MS
President and Executive Board
Chairman

Sandeep Allam is the President and Executive Chairman of the Board, and Co-founder of Syra Health. Sandeep brings more than 20 years of valuable business experience to Syra Health. He has successfully created, managed, and grown numerous companies and organizations including STLogics and Blue Agilis. Sandeep has earned his reputation as a thought leader in the fields of emerging IT, renewable energy, and healthcare. He holds a Master of Science degree in Information Technology from Ferris State University.



Priya Prasad, MBA
Chief Operating Officer & Chief
Financial Officer


Priya Prasad is the Chief Operating Officer and Chief Financial Officer for Syra Health. She has served as the President of STLogics Corporation for nearly 20 years. She is a board member for RADcube and Skill Demand Corp. since January 2015, and an advisory board member at Blue Agilis Corp. She holds an MBA from the University of Massachusetts – Boston, and a Master of Science degree and Bachelor of Science degree in Environmental Science from Bangalore University and Mount Carmel College, respectively.

SYRA HEALTH BOARD OF DIRECTORS

Sherron Rogers	Ms. Rogers has over 19 years of senior leadership experience. Since March 2022, Ms. Rogers has served as the Chief Financial Officer of Johns Hopkins All Children's Hospital. Previously, from August 2020 to March 2022, Ms. Rogers served as the Chief Financial Officer and Chief Strategy Officer of Eskenazi Health, a public hospital that offers a comprehensive range of inpatient, primary and specialty care services.
Andrew M. Dahlem, PhD	Since November 2018, Dr. Dahlem has served as Senior Research Professor of Medicine at the Indiana University School of Medicine and also served as Chief of the Division of Clinical Pharmacology until May 2022. Dr. Dahlem is co-founder and has served as an advisor to Gate Neurosciences, a biotechnology company focused on new therapies for treatment resistant depression, since April 2019 and President of Dr. Dahlem Consulting LLC, advising on the discovery and development of novel therapeutics for academia, biotech and the pharmaceutical industry since May 2018. Furthermore, Dr. Dahlem also served as Vice President of Research Operations and Chief Operating Officer of Lilly Research Laboratories and Lilly Research Laboratories Europe at Eli Lilly and Company until his retirement in December 2017.
Vijayapal R. Reddy, DABT, DVM, PhD	Dr. Reddy is a drug development professional with over 30 years of experience in drug discovery and development in global pharmaceutical industry. Since August 2017, Dr. Reddy has served as an advisor as well as a Director of VIPRA, LLC, a consulting company. Dr. Reddy currently serves as a consultant for various pharmaceutical, biotechnology and vaccine companies. From 2007 to 2017, Dr. Reddy served as a Senior Researcher Advisor/Executive Director at Lilly Research Laboratories, at Lilly, where he led nonclinical safety and regulatory assessments on several cross functional programs at different stages of development.
Ketan Paranjape	Since April 2018, Dr. Paranjape has served as the Vice President of Roche Information Solutions, and since September 2020, he has served as the Vice President of Commercial Business Operations, Business Intelligence and Analytics at Roche Diagnostics, a multinational healthcare company. Since September 2019, Dr. Paranjape has been included on the World Health Organization's roster of digital health experts which was established to advise the World Health Organization Secretariat.
Avutu S. Reddy, PhD	Dr. Reddy has over 20 years of leadership experience in both in research and development and business. Since October 2017, Dr. Reddy has served as the Strategic Scientific and Emerging Business Intelligence Leader at Corteva Agriscience (NYSE: CTVA), an agricultural chemical and seed company and spin-off from Dow-DuPont. Dr. Reddy joined Dow AgroSciences in January 1999 and served in various roles including R&D Innovation Incubator Leader from January 2015 to December 2017; Competitive Intelligence Leader from January 2009 to December 2017; Global Traits Discovery Platform Leader from January 2005 to December 2008; Global Leader of Molecular Biology and Traits from January 2002 to December 2004; and Global Leader of Genomics from January 1999 to December 2001.

ORGANIZATION HISTORY

- **⊘** Healthcare Company
- Headquartered in Carmel, Indiana
- **⊘** Incorporated in 2020
- **⊘** Women-Led
- Became publicly traded on the Nasdaq on Octobe 2023
- **⊘** Ticker Symbol: SYRA





Improving Healthcare

THANK YOU



christined@syrahealth.com



317-385-9227



www.syrahealth.com